Smiths Investors - SMIN

Smiths Investors - SMIN

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type
Smiths Group Plc SMIN London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
24.00 1.53% 1,591.00 16:35:26
Open Price Low Price High Price Close Price Previous Close
1,580.00 1,576.50 1,593.50 1,591.00 1,567.00
more quote information »
Industry Sector

Top Investor Posts

broadwood: Smiths Group, the FTSE-100 in‎dustrial conglomerate, is close to calling off talks with a rival about a £7bn merger that would have created a transatlantic healthcare giant. Sky News has learnt that Smiths is leaning towards a decision to halt negotiations with Nasdaq-listed ICU Medical about a tie-up more than two months after they got underway. A final decision has yet to be made by Smiths' chief executive, Andy Reynolds Smith, and a person close to the British company insisted on Tuesday night that any change in its position would be announced immediately to the London Stock Exchange. Banking sources said that news of the talks between Smiths and ICU, which were confirmed after Sky News revealed them in May, had prompted Baxter International, another US healthcare company, to express an interest in buying Smiths Medical outright. It was unclear whether any live talks were still taking place between Smiths and Baxter or any other potential suitors. News of the discussions was welcomed by Smiths investors in May amid hopes that the company was close to unlocking part of the value bound up in its conglomerate structure. Since then, both Smiths and ICU are said to have tabled a string of proposals about how a combination could work, with varying degrees of governance and management control being held by the two parties. ICU, which makes devices used in infusion therapy and oncology, is thought to have been keen on a formal merger of the businesses rather than a more straightforward joint venture. The Nasdaq-listed ICU has a market value of $6bn‎ (£4.6bn), while Smiths Medical was likely to have been valued at more than £2.5bn (£1.9bn) in a transaction. The US-based company has a long track record of takeovers including the $900m purchase completed last year of Pfizer's Hospira Infusion Systems arm. Smiths Medical, which also supplies advanced devices to healthcare markets around the world, accounts for just under 30% of the group's revenues, making it the company's largest unit on that basis. Its performance has been rocky in recent years, with revenue in the half-year to January down 5% to £451m. Last month, Smiths Group shares tumbled after the company said that changes to European Union rules on medical devices would hurt sales from 2020. The company said this year that it was making "significant progress on its return to growth" in the medical‎ arena but cautioned that higher research and development costs were having an impact on short-term profitability. Smiths also operates in areas such as security detection, making much of the body-scanning equipment used at airports around the world. In total, it has five main divisions‎, which also include John Crane, a provider of engineering solutions for energy and other process industries. The company's structure has long been a source of consternation for some investors and analysts, although talk of a takeover or break-up has never resulted in significant corporate activity. In recent months there has been growing talk among City investors that Smiths is likely to attract the attention of an activist investor keen on pressing more aggressively for a break-up, although its shares have generally performed strongly in recent months and are up modestly over the last year. Such activism has become increasingly common in the UK‎, with companies including FirstGroup, the transport operator, drug-maker Shire and Costa Coffee-owner Whitbread all the subject of current campaigns. Mr Reynolds Smith, who joined the company in 2015 from GKN, the engineering firm which has just been bought by Melrose Industries, is under pressure to demonstrate that its existing structure continues to deliver benefits to shareholders.
philanderer: Industrial technology firm Smiths Group has spent most of the past year offloading different businesses but the rumour doing the rounds in the City today was it could soon change tack. On a quiet Friday, the hearsay was that the FTSE 100 company has its eye on Accelerate Diagnostics, a little-known US medical technology firm worth $1.3 billion (£1 billion) on Nasdaq. The Arizona-based company is working towards commercialising technology which helps to diagnose infectious diseases sooner. Its shares rose 5% yesterday against a falling market with trading volumes much higher than normal. Although Smiths’ name is in the frame for a potential tilt, larger US groups have a head-start on it, sources said. Frontrunners for Accelerate are said to be Thermo Fisher Scientific and Boston Scientific — both are much larger and have far more firepower than Smiths, whose operations range from energy services to specialist medical devices. It has sold several non-core business over the past year to buoy the balance sheet. After recent falls, Accelerate’s shares are now changing hands for only $23 a pop. Gossips said Accelerate and its directors, who control a large chunk of the company, would hold out for at least $35 a share. Smiths and Accelerate said they do not comment on speculation. Shares in Smiths were down 10.15p to 1553p, tracking UK stocks lower as investors digested the Barcelona terror attack and the increasingly chaotic nature of Donald Trump’s presidency. London Ev Standard HTTPS://
philanderer: As Smiths Group updates the market Graham Spooner, our investment research analyst, explains what it could mean for investors: Smiths Group reported increase in profits and revenues and stuck to its full-year outlook boosted by growth in its detection unit The group’s new strategy announced last September is being implemented and aims to increase competitiveness and outperformance in its markets. We recommend Smiths Group as a ‘buy’ for medium risk investors seeking a balanced return HTTPS://
philanderer: Telegraph market report: .....Elsewhere, forecast-beating half-year results lifted engineering firm Smiths to the top of the leaderboard, up 45p to £16.01. Operating profit rose 27pc to £277m boosted by cost cuts and growth in its detection unit. The group also maintained its full-year outlook. Following the upbeat results, Credit Suisse increased its price target from £16 to £17.40, adding its investment case “remains attractive”. HTTP://
skyship: Perhaps use this link to search the article regarding stake-building by ValueAct Cap. Man... The "Quiet Activist" This week and for the first time, many UK retail investors will have become familiar with the name Jeffrey Ubben, whose ValueAct Capital Management has been linked to two mainstays of British industry - Rolls-Royce and, today, Smiths Group. But ValueAct isn't just another hedge fund looking to make a quick buck. Dubbed the "Quiet Activist", Ubben prefers to be seen as a helpful contributor rather than an annoying agitator. Indeed, ValueAct's long-term approach is underlined by the fact that Ubben likens ValueAct’s style to bringing a private-equity strategy to a public company. ValueAct usually makes only three to four new investments in one year. It often holds about 15 positions and the average holding period for each position is about three years. Often worming its way onto the board of the target company, ValueAct then uses argument and persuasion - all conducted very privately - to cajole executives around to its way of thinking. As of September 2014, ValueAct, which has pressed for changes at 75 companies since Ubben co-founded the firm in 2000, claims to have generated almost $11 billion in gross profits for its investors. And with $14 billion under management, it is larger than most of its activist peers. In short, ValueAct and Ubben are worthy of investors' attention. ValueAct's arrival on the shareholder register of Smiths Group (LON:SMIN) comes after years of break-up speculation. Smiths' conglomerate structure is a relic of the past, as it flies in the face of current financial theory, which holds that businesses are more valuable as separate entities when there are no easily identifiable synergies. In Smiths' case, with businesses as diverse as medical equipment, airport scanners and industrial seals all under the same umbrella, the argument for a break-up seems as good as any. According to the most recent set of results, divisional operating margins varied from 9.2% to 23.2%, while return on capital employed ranged from 3.1% to 33.7%. With the Smiths share price having struggled to go anywhere over the past ten years, it would be reasonable to assume that other shareholders may be receptive to the idea of a break-up, or at the very least some kind of restructuring, which could help realise value. Previous attempts to shake things up at Smiths have met with failure, but this time could be different for several reasons: 1) ValueAct is the third activist investor to join the Smiths board, as it joins Harris Associate, with a 7.4% stake, and RWC, with 1.4%, making a likely combined holding of over 10% by activists. 2) Rising interest rates could reduce the value of the firm's pension deficit, which has in the past acted as a major stumbling block to change. 3) Smiths recently acquired a new chief executive from GKN Automotive who will no doubt want to make his mark. In a note issued today, Credit Suisse calculated a break-up value of 1,500p per share for Smiths, based on implied valuations of 17.8 times 2016 EV/EBITA for the medical arm - which is consistent with recent take-out multiples of Covidien and CareFusion - 16.1 times for the Detection business, 13.4 times for Interconnect and 13.8 times for Flex Tek. In my opinion, a break-up, or at the very least some kind of major restructuring, is inevitable in the long run. Smiths is simply a dinosaur from a bygone age. In the meantime, investors can sit back and collect a useful 3.6% dividend yield. Best regards, James Faulkner
jeffcranbounre: Smith DS is featured on today's ADVFN podcast. To listen to the podcast click here> In today's podcast: - Technical Analyst and PR at Zak Mir chatting and charting Quindell and it’s good news if you’re Quindell investor, Nanoco, Afren, Blur and should you invest in BP or Royal Dutch Shell? Zak on Twitter is @ZaksTradingCafe - And the micro and macro news including: Quindell #QPP Afren #AFR Royal Bank of Scotland #RBS Blur #BLUR Nanoco #NANO BP #BP. Royal Dutch Shell #RDSB #MONY GlaxoSmithKline #GSK Synthomer #SYNT JD Sports #JD. HSBC #HSBA Google #GOOG Standard Chartered #STAN Vedanta Resources #VED MyCelx Technologies #MYXR IG Group #IGG Shire #SHP AstraZeneca #AZN Smith (DS) #SMIN Dignity #DTY Tristel #TSTL Lancashire #LRE Wolseley #WOS Robert Walters #RWA Every Tuesday is Ten Bagger Tuesday on the podcast. If you know of a stock, whose share price has the potential to increase ten fold, just click the link below. Ten Bagger Tuesday (All it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). Once a week, on a Friday, I feature a tip from a listener to this podcast, if you'd like to suggest a stock click the link below: Suggest a stock (Again all it involves is filling out a form that will take you around 5 minutes and you don't personally appear on the podcast). You can subscribe to this podcast in iTunes by clicking HERE To follow me on Twitter click HERE As a listener to the ADVFN podcast you can take advantage of some exclusive first year discounts on popular subscriptions: Bronze - £50 (normally £73.82/year) Silver - £145 (normally £173.71/year) Level 2 - £350 (normally £472.94/year) Call 0207 0700 961 and ask for the ADVFN Podcast discount to take advantage of these reduced rates or just CLICK HERE for more information. Please DO NOT buy any stock recommended in this podcast basely solely on what you hear. The opinions in this podcasts are just that, opinions. Please do you own research before investing. Justin    
bromos: FT quote today: The Lex Column: Smiths Group (talk of stake building by activist investor Samuel Heyman)
bromos: James93 and Ringer FT suggests today "Talk that an activist investor is amassing a stake in Smiths Group" and Daily Express: "Smiths Group takes off on hopes of a break-up" This could explain the rise in part at least.
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210725 16:51:50